The latest announcement is out from Lyell Immunopharma (LYEL).
Lyell Immunopharma, Inc. has shared promising initial results from its Phase 1 trial of LYL797, a novel CAR T-cell therapy targeting advanced solid tumors. The treatment, which incorporates anti-exhaustion technology, showed a 40% objective response rate in triple-negative breast cancer at the highest tested dose, with a clinical benefit rate of 60%. With manageable side effects, the therapy demonstrated potential, evidenced by the ability of the enhanced CAR T cells to expand, infiltrate, and persist in tumors. The company continues to investigate the treatment’s efficacy and safety, with encouraging translational data supporting its technology’s role in reducing T-cell exhaustion and maintaining a stem-like phenotype in the treated patients.
Learn more about LYEL stock on TipRanks’ Stock Analysis page.
